Profiling and leveraging bystander T cells within the tumor microenvironment
Profiling and leveraging bystander T cells within the tumor microenvironment
批准号:
10554642
负责人:
NICHOLAS JOSEPH MAURICE
金额:
$8.77万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-02-01 至 2026-01-31
关键词:
3-DimensionalActivities of Daily LivingAdaptive Immune SystemAdoptive TransferAgeAnatomyAnimal ModelAntigensAntitumor ResponseAutoimmunityBlocking AntibodiesBystander EffectCD8-Positive T-LymphocytesCTLA4 geneCXCR3 geneCancer ModelCause of DeathCell Surface ProteinsCell physiologyCellsCessation of lifeChronicColorComplementCytolysisDiagnosisDiseaseExcisionFailureFlow CytometryFunctional disorderGoalsHomeostasisHumanImmuneImmune TargetingImmune responseImmune systemImmunofluorescence ImmunologicImmunotherapyImpairmentInfiltrationInflammationInterferon Type IIInterventionKnock-outLeadLigationMajor Histocompatibility ComplexMalignant NeoplasmsMediatingMethodsMissionModalityNatural Killer CellsOutcomeOutcomes ResearchPathogenesisPatientsPhasePhenotypePlayPopulationPositioning AttributeProcessProteinsRadiationReceptor SignalingRelapseResearchRoleSecond Primary CancersSolid NeoplasmSpecificityStressSurveysT cell responseT-Cell ReceptorT-LymphocyteTestingTherapeuticTissuesToxic effectTransgenic OrganismsTransplantationTumor AntigensTumor-Infiltrating LymphocytesUnited States National Institutes of HealthUp-RegulationWorkanti-tumor immune responseantigen-specific T cellscancer immunotherapycancer therapychemokine receptorchemotherapychimeric antigen receptorchimeric antigen receptor T cellschronic infectioncongenicconventional therapycytokinecytotoxicdesignexhaustionexperimental studygenetically modified cellsimmune checkpoint blockadeimprovedinhibitormigrationmortalitymouse modelneoplasm immunotherapyneoplastic cellprogrammed cell death protein 1receptorreceptor bindingrecruitresponseside effectstandard of caresuccesstooltumortumor heterogeneitytumor microenvironmenttumor specificity
中文摘要
项目摘要/摘要
癌症仍然是美国境内死亡的主要原因,四分之一的死亡是由癌症造成的。免疫疗法有
开启了癌症治疗的新时代,利用免疫系统的效力来限制癌症,而不是
传统疗法的许多副作用。这些免疫疗法主要针对免疫
肿瘤抗原的特异性反应(TAG)。尽管标签特异性T细胞免疫疗法已被证明是有效的
作为抗击癌症的工具,它们的成功取决于具体情况,在大多数实体肿瘤中显示出有限的疗效。
这在很大程度上是由于慢性T细胞受体(TCR)与同源标签结合,导致永久细胞
功能障碍。实体瘤占癌症病例和死亡的大多数,因此开发其他肿瘤是必要的。
免疫疗法中的细胞模式。最近,已经变得明显的是,标签非特定的“旁观者”T
在实体瘤中可以观察到细胞,并且细胞的数量经常超过标签特异性T细胞。尽管它们在肿瘤中的功能
尚不清楚,旁观者T细胞一旦被炎症激活就能发挥细胞毒效应功能
上下文的关系。我独特的方法利用T细胞和定义的T细胞受体(TCR),使我能够确定
指示旁观者T细胞进入肿瘤的机制以及它们是否保持对
刺激曾经驻留在肿瘤上。为了了解肿瘤微环境的异质性,我将使用
实体瘤的多种动物模型。我的目标有两个:首先,我想测试旁观者T细胞
转移到肿瘤,以及它们是否由于无法识别标签而免于调节失调。第二,我
我想测试旁观者T细胞的二分性效应是否可以在治疗上被利用来提高抗-
肿瘤反应。在动态平衡状态下,旁观者T细胞可以简单地拒绝其他免疫细胞访问靶点,
阻碍抗原(Ag)特异性免疫反应。一旦被炎症激活,旁观者T细胞就会迅速
获得效应器功能,并以与生俱来的方式直接杀死目标细胞。为了实现这些目标,我将
利用我在28色流式细胞术方面的专业知识来询问细胞的表型、激活和功能能力。
我将用三维免疫荧光来补充我对流式细胞术的使用,这将揭示出
肿瘤内的解剖免疫细胞组织。假设:我的中心假设是旁观者T细胞
在实体肿瘤中仍然具有功能,并且可以特别用于癌症的治疗。我要测试一下这个
通过两个独立的目标进行假设:目标1:检验旁观者T细胞被招募到
肿瘤通过CXCR3,并在肿瘤微环境中保持功能。目标2:检验反-反病毒的假设
激活旁观者T细胞或靶向清除驻留组织可增强肿瘤免疫应答
旁观者。我提议的实验将阐明旁观者T细胞在有无肿瘤中的作用
干预措施,目标是制定干预措施以改善癌症结果,这与
美国国家情报局和美国国立卫生研究院的任务。
英文摘要
PROJECT SUMMARY/ABSTRACT
Cancer remains a leading cause of mortality within the US, responsible for 1 in 4 deaths. Immunotherapies have
ushered in a new age of cancer treatment, leveraging the potency of the immune system to restrict cancer without
many of the side effects of conventional therapies. These immunotherapies have primarily targeted immune
responses specific for tumor antigens (tAg). Although tAg-specific T cell immunotherapies have proven powerful
tools in combatting cancer, their success is context-dependent, displaying limited efficacy in most solid tumors.
This is largely owed to chronic T cell receptor (TCR) binding to cognate tAg, leading to permanent cellular
dysfunction. Solid tumors comprise the majority of cancer cases and deaths, thus, it is essential to exploit other
cellular modalities in immunotherapies. Recently, it has become apparent that tAg-nonspecific “bystander” T
cells are observed and often outnumber tAg-specific T cells in solid tumors. Although their function within tumors
is unknown, bystander T cells can exert cytotoxic effector function once activated by inflammation in a number
of contexts. My unique approach leveraging T cells with defined T cell receptors (TCRs) allows me to determine
the mechanisms that dictate bystander T cell entry into the tumor and if they maintain the ability to respond to
stimulation once tumor-resident. To appreciate the heterogeneity of tumor microenvironments, I will employ
multiple animal models of solid tumors. My objectives are two-fold: First, I want to test how bystander T cells
migrate to the tumor and if they are spared from dysregulation due to their inability to recognize tAg. Second, I
want to test if the dichotomous effects of bystander T cells can be therapeutically leveraged to improve anti-
tumor responses. At homeostasis, bystander T cells can simply deny other immune cells access to targets,
hindering antigen (Ag)-specific immune responses. Once activated by inflammation, bystander T cells rapidly
acquire effector function and directly kill target cells in an innate-like manner. To achieve these objectives, I will
employ my expertise in 28-color flow cytometry to interrogate cell phenotype, activation, and functional capacity.
I will complement my use of flow cytometry with 3-dimensional immunofluorescence, which will uncover sub-
anatomic immune cell organization within the tumor. Hypothesis: My central hypothesis is that bystander T cells
in solid tumors remain functional and can be therapeutically leveraged in cancer specifically. I will test this
hypothesis through two independent aims: AIM 1: Test the hypothesis that bystander T cells are recruited into
tumors by CXCR3 and remain functional in the tumor microenvironment. AIM 2: Test the hypothesis that anti-
tumor immune responses can be enhanced by activated bystander T cells or targeted depletion of tissue-resident
bystanders. My proposed experiments will elucidate the role of bystander T cells in tumor both with and without
interventions, with the goal of developing interventions to improve cancer outcomes, which is in alignment with
the mission of the NCI and NIH.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Profiling and leveraging bystander T cells within the tumor microenvironment
-
批准号:10573231
-
项目类别:
-
资助金额:$9.04万
-
财政年份:2022
-
负责人:NICHOLAS JOSEPH MAURICE
-
依托单位:
Profiling and leveraging bystander T cells within the tumor microenvironment
-
批准号:10414302
-
项目类别:
-
资助金额:$1.32万
-
财政年份:2021
-
负责人:NICHOLAS JOSEPH MAURICE
-
依托单位:
Profiling and leveraging bystander T cells within the tumor microenvironment
-
批准号:10015245
-
项目类别:
-
资助金额:$3.97万
-
财政年份:2019
-
负责人:NICHOLAS JOSEPH MAURICE
-
依托单位:
海外基金